SAFIR-PI3K A Phase II Randomized Maintenance Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy in PIK3CA Mutated Advanced Breast Cancer

NCT03386162 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

31

Enrollment

OTHER

Sponsor class

Stopped Study was halted Prematurely for low recruitment.

Conditions

Breast Cancer, PI3K, Alpelisib

Interventions

DRUG: Alpelisib
DRUG: Chemotherapy

Sponsor

UNICANCER